Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales	$ 185,246,025	$ 138,454,924
Cost of sales	87,892,579	73,667,333
Gross profit	97,353,446	64,787,591
Operating expenses:
Research and development	5,935,514	4,224,891
Marketing	25,189,326	11,150,514
Selling, general, and administrative	54,913,441	48,397,419
Write-off of acquired Drawbridge in-process research and development	1,563,015
Income from operations	9,752,150	1,014,767
Other (income) expense:
Interest expense, net	449,908	1,125,472
Guarantee fees	336,915	243,040
Change in fair value of warrant liability	(1,872,364)	1,912,487
Loss on Drawbridge Transaction	165,998
Other (income) expense, net	(249,082)	1,119
Total other (income) expense, net	(1,168,625)	3,282,118
Income (loss) before income taxes and loss from equity interests in unconsolidated affiliates	10,920,775	(2,267,351)
Income tax expense	411,919	176,758
Net income (loss) before loss from equity interests in unconsolidated affiliates	10,508,856	(2,444,109)
Loss from equity interests in unconsolidated affiliate	(3,664,058)	(1,509,704)
Net income (loss)	6,844,798	(3,953,813)
Net income non controlling interest	(408,625)	(596,067)
Net income (loss) attributable to Thorne HealthTech, Inc.	7,253,423	(3,357,746)
Undistributed earnings attributable to Series E convertible preferred stockholders	(3,507,892)
Net income (loss) attributable to common stockholders	3,745,531	(3,357,746)
Net income (loss) attributable to common stockholders - Diluted	$ 3,349,308	$ (3,357,746)
Earnings (loss) per share:
Basic	$ 0.14	$ (0.34)
Diluted	$ 0.10	$ (0.34)
Weighted average common shares outstanding:
Basic	27,478,411	9,985,800
Diluted	32,328,565	9,985,800